

not in compl. of new amdt. procedures
No E. On page 2, line 24, change "treatmen" to --treatment--, and change "agreater" to --a greater--.

IN THE CLAIMS

Please re-write claims 5, 10 and 36 as follows:

a2 5.(amended) The method of claim 1, wherein the amount of ribavirin administered in the second treatment period is from about 800 to 1200 mg per day.

a3 10.(amended) The method of claim 1, wherein the pegylated interferon-alfa administered is pegylated interferon alfa-2b, and wherein the induction dosing amount of pegylated interferon alfa-2b administered in the first treatment time period is in the range of 0.5 to 1.5 micrograms per kilogram twice a week ("BIW") for at least four weeks, and the amount of pegylated interferon alfa-2b administered in the second treatment time period is in the range of 0.5 to 1.5 micrograms per kilogram per week for up to forty-four weeks.

a4 37.(amended) The method of claim 27, wherein the amount of ribavirin administered in the first and second treatment time periods is from about 800 to 1200 mg per day.

REMARKS

PRIORITY CLAIM

new claim 31
Applicants are amending the specification page 1 to add the specific reference to claim the benefit to the prior U.S. Provisional Application SN 60/112,773, filed 12/18/1998.

SPECIFICATION OBJECTIONS

The specification is objected to in that the word "alpha" is allegedly misspelled as "alfa". The use of alfa in reference to interferon is a term used by those skilled in the art to which is application pertains. Applicants enclose herewith two pages of the 1998 PDR: on page 2489 the Roche brand of interferon alfa 2a product is disclosed, and on page 2637, whereat the Schering brand of interferon alfa-2b product is disclosed. This supports Applicants' assertion that one skilled in the art would understand that "interferon alfa" accurately describes interferon- α products.